scholarly journals Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer

2018 ◽  
Vol 38 (4) ◽  
Keyword(s):  
Lung Cancer ◽  
Estrogen Receptor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Estrogen Receptor Α ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung

scholarly journals level of estrogen receptor α and β expression and coexpression in non-small cell lung cancer tissue

2019 ◽  
Vol 17 (4) ◽  
pp. 111-114
Author(s):  
T. A. Bogush ◽  
O. M. Ryabinina ◽  
M. I. Papulina ◽  
E. A. Bogush ◽  
A. N. Grishanina ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Estrogen Receptor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Estrogen Receptor Α ◽  
Small Cell ◽  
Cancer Tissue ◽  
Lung Cancer Tissue ◽  
Small Cell Lung

scholarly journals Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer

2011 ◽  
Vol 3 (2) ◽  
pp. 462-468 ◽  
Author(s):  
HUAI-LU CHANG ◽  
YU-JEN CHENG ◽  
CHUNG-KUANG SU ◽  
MENG-CHIH CHEN ◽  
FU-HSIN CHANG ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Estrogen Receptor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Estrogen Receptor Α ◽  
Small Cell ◽  
Small Cell Lung ◽  
Estrogen Receptor Α Gene

scholarly journals Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung Cancer

2005 ◽  
Vol 11 (14) ◽  
pp. 5084-5089 ◽  
Author(s):  
Hideki Kawai ◽  
Akira Ishii ◽  
Kiyotada Washiya ◽  
Toshiko Konno ◽  
Hiroto Kon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Estrogen Receptor ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Estrogen Receptor Α ◽  
Small Cell ◽  
Small Cell Lung

Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer

Steroids ◽  
2016 ◽  
Vol 113 ◽  
pp. 5-13 ◽  
Author(s):  
Kaja Skjefstad ◽  
Thea Grindstad ◽  
Mehrdad Rakaee Khanehkenari ◽  
Elin Richardsen ◽  
Tom Donnem ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Estrogen Receptor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Estrogen Receptor Α ◽  
Small Cell ◽  
Small Cell Lung ◽  
Aromatase Expression ◽  
Prognostic Relevance

Current and future therapeutic approaches in locally advanced (stage III) non[ndash ]small cell lung cancer

2002 ◽  
Vol 29 (3 Suppl 12) ◽  
pp. 10-16 ◽  
Author(s):  
Angela Davies ◽  
David R. Gandara ◽  
Primo Lara ◽  
Zelanna Goldberg ◽  
Peter Roberts ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iii ◽  
Advanced Stage ◽  
Therapeutic Approaches ◽  
Small Cell Lung

scholarly journals Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011)

2017 ◽  
Vol 35 (5) ◽  
pp. 529-535 ◽  
Author(s):  
Cathy J. Bradley ◽  
K. Robin Yabroff ◽  
Angela B. Mariotto ◽  
Christopher Zeruto ◽  
Quyen Tran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Antineoplastic Agents ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Medicare Data ◽  
Outcome Information ◽  
New Diagnosis

Purpose Multiple agents for advanced non–small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163). We estimated the adjusted percentage of patients who received each agent, days while on treatment, survival, and spending in the 12 months after diagnosis. Results During the 12-year study period, a marked shift in treatment occurred along with a rapid adoption of pemetrexed (39.2%), erlotinib (20.3%), and bevacizumab (18.9%) and a decline in paclitaxel (38.7%), gemcitabine (17.0%), and vinorelbine (5.7%; all P < .05). The average total days on therapy increased by 5 days (from 103 to 108 days). Patients who received bevacizumab, erlotinib, or pemetrexed had the longest treatment durations on average (approximately 146 days v 75 days for those who did not receive these agents). Approximately 44% of patients received antineoplastic agents in the last 30 days of life throughout the study period. Acute inpatient spending declined (from $29,376 to $23,731), whereas outpatient spending increased 23% (from $37,931 to $46,642). Median survival gains of 1.5 months were observed. Conclusion Considerable shifts in the treatment of advanced-stage NSCLC occurred along with modest gains in survival and total Medicare spending. More precise outcome information is needed to inform value-based treatment decisions for advanced-stage NSCLC.

Sign in / Sign up

Export Citation Format

Share Document